OpenBilldrug price receipt

NADAC week of 2026-10-14

MYFEMBREE 40 MG-1 MG-0.5 MG TB

FDA nonproprietary name: relugolix, estradiol hemihydrate, and norethindrone acetate

For 30 tablets

Pharmacies pay

$1,357.54 filed

30 × $45.25137 per EA

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

Medicare Part D paid

$1,245.62 filed

30 × $41.52075 per EA, Part D average

Medicare's price is not your price.

Medicare Part D · DSD_PTD_RY26_P04_V10_DY24_BGM.csv · eff. 2024-01-01 to 2024-12-31 · as of 2026-06-25 · retrieved 2026-10-18


The spread

0.92× estimated

Medicare paid 8% less than pharmacies pay.

Part D averages every strength and form sold under “Myfembree” / “Relugolix/Estradiol/Norethindr” into one figure, so it is not specific to this NDC.

OpenBill calculation · DSD_PTD_RY26_P04_V10_DY24_BGM.csv + nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17) · Part D 2024-01-01 to 2024-12-31 (file of 2026-06-25, retrieved 2026-10-18)

Cost-plus estimate

$1,566.17 estimated

$1,357.54 + $203.63 (15%) + $5.00 fee per fill = $1,566.17

This is a model, not a price any pharmacy quoted. Shipping is not included. How it is worked out

OpenBill calculation · nadac-national-average-drug-acquisition-cost-20261014.csv · NADAC eff. 2026-09-23 (file of 2026-10-14, retrieved 2026-10-17)

Open the interactive card Change the quantity, type what you were charged, and see every record in full.

What it is

MYFEMBREE 40 MG-1 MG-0.5 MG TB is how the CMS NADAC file names this product. The FDA NDC Directory lists it as relugolix, estradiol hemihydrate, and norethindrone acetate, under the trade name “Myfembree”.

FDA gives its dosage form as tablet, film coated and its route as oral.

The labeler, the company named on the label, is Sumitomo Pharma America, Inc.

FDA lists it under 3 Established Pharmacologic Classes: Estrogen, Gonadotropin Releasing Hormone Receptor Antagonist and Progestin.

The NADAC file of 2026-10-14 prices it under one NDC (National Drug Code), 72974-0415-01.

NADAC classes it as a brand-name drug (rate-setting class B), and does not mark it as sold over the counter.

What pharmacies pay

Pharmacies pay $1,357.54 for 30 tablets (30 × $45.25137 per EA, rounded to the cent), by the CMS NADAC file of 2026-10-14; that price took effect on 2026-09-23. That is what pharmacies pay their suppliers, not what they charge you.

NADAC’s explanation code for it: 1, calculated from the most recently completed pharmacy survey.

The NDC

Compared with its class

Its NADAC price is $45.25137 per EA filed.

Of the 104 other products in FDA’s Estrogen class priced per EA, 10 have a higher middle NADAC price and 94 a lower one. The one in the middle is LYLLANA 0.075 MG PATCH, at $8.11285 per EA filed (eff. 2026-09-23).

Of the 65 other products in FDA’s Progestin class priced per EA, 7 have a higher middle NADAC price and 58 a lower one. The one in the middle is NORETHIN-ETH ESTRAD 1 MG-5 MCG, at $0.57994 per EA filed (eff. 2026-09-23).

Prices are compared per unit, whatever the strength or dose, and a class is not a list of substitutes.

CMS NADAC · nadac-national-average-drug-acquisition-cost-20261014.csv · eff. 2026-09-23 · as of 2026-10-14 · retrieved 2026-10-17

What Medicare paid

Medicare Part D paid $1,245.62 for 30 tablets, at an average of $41.52075 per EA in 2024 (2024-01-01 to 2024-12-31) for “Myfembree” and “Relugolix/Estradiol/Norethindr”, every strength and form sold under that name together (Medicare Part D Spending by Drug, file of 2026-06-25).

That average covers 1,412 Part D claims (fills, including refills) for 2024-01-01 to 2024-12-31, across every maker, strength and form under the name.

Medicare's price is not your price.

What to ask at the counter

None of these figures is your price: what you pay depends on your pharmacy, your insurance, coupons and discounts.

Questions

Why is the comparison with Medicare for MYFEMBREE 40 MG-1 MG-0.5 MG TB labelled estimated?
Beyond what the card shows, the records give these reasons: The Part D figure covers 2024-01-01 to 2024-12-31; the NADAC price is from the file of 2026-10-14. Part D spending basis, as the Part D record states it: Part D 2024 average spend per dosage unit for Myfembree / Relugolix/Estradiol/Norethindr: all makers, strengths, forms and routes combined, claim-weighted; gross cost incl. dispensing fees and patient pay, before rebates. Unit taken as NADAC's EA. Joined on brand name.